Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 20

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 3
Chunk 20
---
 achievement of a specific milestone under the Gloria License Agreement and for certain product supply, which was due during
2024. In addition, the planned studies of motixafortide in China under the Gloria License Agreement are currently not advancing according
to schedule and it is unclear when such studies will be initiated, if at all. There can be no assurance that Gloria will meet its payment
obligations or any other obligations under the Gloria License Agreement.

Any collaborative partners may in the future shift their priorities
and resources away from our therapeutic candidates or seek to renegotiate or terminate their relationships with us. If any collaborator
fails to fulfill its responsibilities in a timely manner, or at all, our research, clinical development, manufacturing or commercialization
efforts related to that collaboration could be delayed or terminated, or it may be necessary for us to assume responsibility for expenses
or activities that would otherwise have been the responsibility of our collaborator. If we are unable to establish and maintain collaborative
relationships on acceptable terms or to successfully transition terminated collaborative agreements, we may have to delay or discontinue
further development of one or more of our therapeutic candidates, undertake development and commercialization activities at our own expense
or find alternative sources of capital.

If competitors develop and
market products that are more effective, safer or less expensive than our current or future therapeutic candidates, our prospects will
be negatively impacted.

The life sciences industry is highly competitive, and we and our
licensees face significant competition from many pharmaceutical, biopharmaceutical and biotechnology companies that are researching and
marketing products designed to address the indications for which we are currently developing motixafortide or for which we may develop
therapeutic candidates in the future. Specifically, we are aware of other companies that currently market and/or are in the process of
developing products that address stem cell mobilization, solid malignancies and skin lesions. In particular, during 2023, the last to
expire patent for Mozobil and uses thereof, the standard of care for stem cell mobilization expired and as a consequence there are several
generic versions on the market. Successful commercialization of APHEXDA will in part require that our licensees are able to overcome competition
from Mozobil and its generic versions.

13

Any therapeutic candidates that we successfully develop and commercialize
will compete with existing therapies and new therapies that may become available in the future. The key competitive factors affecting
the success of each therapeutic candidate, if approved, is likely to be their safety, efficacy